The Effect of Shock Therapies on Health-Related Quality of Life in Patients with Implantable Cardioverter-Defibrrillator

INTRODUCTION: Implantable cardioverter defibrillators (ICDs) reduce mortality from sudden cardiac death (SCD) effectively. However, ICD discharge, whether appropriate or inappropriate, represents a particularly challenging psychological event and is associated with poor quality of life (QoL). We aimed to investigate the association of shock and the health-related QoL. METHODS: Patients implanted with either single, dual chamber ICDs or CRT-D devices were included. When they presented at our clinic for regular device follow-up, they completed the Short-Form Health Survey 36 (SF- 36) at baseline and 12 months. Clinical parameters and device measurements were recorded. RESULTS: A total of 217 patients, including 161 (74%) males with a mean age of 62±12 years, were included in the study. We excluded 10 (4.6%) patients that died during the follow-up. The mean age of the remaining 207 patients (53 female and 154 male) was 62±12 years. During the follow-up, 26 (12.6%) patients experienced shock therapy. Six-teen of them had appropriate and 10 of them had inappropriate shocks. Two or more shocks were delivered in 18 (8.7%) patients. Health status patterns were poor in patients received shock therapies during follow-up period. DISCUSSION and CONCLUSION: ICD shocks were associated with impaired health- related QoL. So, routine consideration of psychosocial situation needs to be integrated into the clinical care of ICD patients.

İmplantabl Kardiyoverter-Defibrilatör Takılan Hastalarda Şok Tedavisinin Hasta Sağlık İlişkili Yaşam Kalitesine Etkisi

GİRİŞ ve AMAÇ: İmplantabl kardiyoverterdefibrilatörler (İKD' ler) ani kardiyak ölümün önüne geçerek, mortaliteyi etkin bir şekilde azaltmaktadır. Bununla birlikte, uygun ya da uygunsuz, İKD şoklaması, özellikle aşılması zor psikolojik süreçlere yol açar ve de kötü yaşam kalitesi ile ilişkilidir. Çalışmamızda, şoklama ile sağlık ilişkili yaşam kalitesi arasındaki ilişkiyi göstermeyi amaçladık. YÖNTEM ve GEREÇLER: Tek, iki ya da üç odacıklı (Kardiyak resenkronizasyon tedavisi-defibrilatör (KRTD) ) İKD implante edilmiş hastalar dahil edildi. Kliniğimize rutin cihaz kontrolü için başvuran hastalar, başvuruda ve 12. ayda Kısa Form-36 sağlık anketini tamamladılar. Klinik parametreler ve cihaz ölçümleri kayıt altına alındı. BULGULAR: Yaş ortalaması 62±12 olan, 161'i (74%) erkek toplam 217 hasta çalışmaya dahil edildi. Takiplerde ölüm gerçekleşen 10 (4.6%) hasta çalışma dışına alındı. Kalan 207 hastanın yaş ortalaması 62±12 idi. Takiplerde 26 (12.6%) hasta şoklama tedavisi aldı. 16 hasta uygun; 10 hasta is uygunsuz şok tedavisi aldı. 18 hastada 2 ya da daha fazla şok tedavisi saptandı. Sağlık durumu parametreleri, şoklama tedavisi gören hastalarda daha kötü saptandı. TARTIŞMA ve SONUÇ: İKD şoklama tedavisi, kötüleşmiş hasta yaşam kalitesi ile ilişkilidir. Dolayısıyla, rutin psikolojik durum değerlendirmesi, İKD hastalarının klinik takiplerine dahil edilmelidir.

Kaynakça

1. Greenberg H, Case RB, Moss AJ et al. MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic DefibrillatorImplantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43: 1459-65.

2. Bristow MR, Saxon LA, Boehmer J et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.

3. Are implantable cardioverter-defibrillators or drugsmore effective in prolonging life? The Antiarrhythmics Versus Implantable Defibrillators(AVID) Trial Executive Committee. Am J Cardiol 1997; 79: 661-3.

4. Sears SF Jr, Todaro JF, Lewis TS et al. Examining the psychosocial impact of implantablecardioverter defibrillators: a literaturereview. Clin Cardiol. 1999;22(7):481-489.

5. Mark DB, Anstrom KJ, Sun JL et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008; 359:999– 1008.

6. Schron EB, Exner DV, Yao Q et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002; 105:589–594

7. Wathen MS, DeGroot PJ, Sweeney MO et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverterdefibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591-6.

8. Sears SF Jr, Conti JB. Quality of life and psychological functioning of ICD patients. Heart 2002;87:488–93.

9. Matchett M, Sears SF, Hazelton G et al. The implantable cardioverter defibrillator: its history, current psychological impact and future. Expert Rev Med Devices 2009;6:43–50.

10. Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.

11. Koçyiğit H, Aydemir Ö, Ölmez N et al. Form-36 (KF-36)'nın Türkçe Versiyonunun. Güvenilirliği ve Geçerliliği. İlaç ve Tedavi Dergisi. 1999; 12: 102-106.

12. Crespo EM, Kim J, Selzman KA. The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a review of the evidence and implications. Am J Med Sci. 2005 May;329(5):238-46.

13. Irvine J, Dorian P, Baker B et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002;144:282-9.

14. Piotrowicz K, Noyes K, Lyness JM et al. Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. Eur Heart J. 2007 Mar;28(5):601-7. Epub 2007 Feb 12.

15. Kamphuis HC, de Leeuw JR et al. Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. Europace. 2003 Oct;5(4):381-9.

16. Volosin KJ, Exner DV, Wathen MS et al. Combining shock reduction strategies to enhance ICD therapy: A role for computer modeling. J Cardiovasc Electrophyisol 2011; 22:280–289.

17. Wollmann CG, Lawo T, Kuhlkamp V et al. Implantable defibrillators with enhanced detection algorithms: Detection performance and safety results from the painfree SST study. Pacing Clin Electrophysiol 2014; 9:1198– 1209

18. Wilkoff BL, Williamson BD, Stern RS et al. Strategic programming of detection and therapy parameters in implantable cardioverterdefibrillators reduces shocks in primary prevention patients results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008; 52:541–550.

19. Moss AJ, Schuger C, Beck CA et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275– 2283.

20. Gasparini M, Proclemer A, Klersy C et al. Effect of Long-detection interval vs standarddetection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: The ADVANCE III randomized clinical trial. JAMA 2013; 309:1903– 1911

21. Guedon-Moreau L, Lacroix D, Sadoul N et al. A randomized study of remote follow-up of implantable cardioverter defibrillators: Safety and efficacy report of the ECOST trial. Eur Heart J 2013; 34:605–614.

22. Sears SF, Whited A, Volosin KJ. Enhancing Patient Care by Estimation and Discussion of Risk for ICD Shock. Pacing Clin Electrophysiol. 2015 Jan;38(1):1-7.

Kaynak Göster

  • ISSN: 2147-0758
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2012

3.7b 2.1b